Abstract
This Letter describes the continued chemical optimization of the VU0453595 series of M1 positive allosteric modulators (PAMs). By surveying alternative 5,6- and 6,6-heterobicylic cores for the 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one core of VU453595, we found new cores that engendered not only comparable or improved M1 PAM potency, but significantly improved CNS distribution (Kps 0.3-3.1). Moreover, this campaign provided fundamentally distinct M1 PAM chemotypes, greatly expanding the available structural diversity for this valuable CNS target, devoid of hydrogen-bond donors.
Keywords:
CNS penetration; M(1); Muscarinic acetylcholine receptor; Positive allosteric modulator (PAM); Structure–activity relationship (SAR).
Copyright © 2016 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Allosteric Regulation / drug effects
-
Animals
-
Central Nervous System / drug effects*
-
Central Nervous System Agents / chemical synthesis
-
Central Nervous System Agents / chemistry
-
Central Nervous System Agents / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Heterocyclic Compounds / chemical synthesis
-
Heterocyclic Compounds / chemistry
-
Heterocyclic Compounds / pharmacology*
-
Molecular Structure
-
Pyridines / chemical synthesis
-
Pyridines / chemistry
-
Pyridines / pharmacology*
-
Pyrroles / chemical synthesis
-
Pyrroles / chemistry
-
Pyrroles / pharmacology*
-
Rats
-
Receptor, Muscarinic M1 / metabolism*
-
Structure-Activity Relationship
Substances
-
Central Nervous System Agents
-
Heterocyclic Compounds
-
Pyridines
-
Pyrroles
-
Receptor, Muscarinic M1
-
VU0453595